Close menu




September 8th, 2021 | 12:28 CEST

PuriflOH, Bayer, Philips - Innovations as yield drivers

  • Investments
Photo credits: pixabay.com

Innovations enrich our everyday lives in many ways. The following companies have developed innovative solutions for health and climate in the broadest sense that help remedy important problems. The focus here is on water, a scarce resource, and air purification, which in times of Corona plays an increasingly important role. Which Company has the best opportunities?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: PURIFLOH LTD | AU0000010548 , BAYER AG NA O.N. | DE000BAY0017 , KONINKL. PHILIPS EO -_20 | NL0000009538

Table of contents:


    PURIFLOH LIMITED - Innovator from Australia with worldwide patents

    Founded in Australia with a US office in Detroit, PuriflOH has developed innovative and globally patented technology for cleaning air, water and surfaces in residential, commercial and industrial settings. According to the Company, PuriflOH has developed the first and only single solution to remove biological and chemical contaminants from the air through a two-step process.

    IP licensing and partnership opportunities with air purification equipment manufacturers for residential, commercial and industrial applications are currently being explored. PuriflOH solutions are easily expandable and, therefore, scalable. In the past, the Company undertook significant research activities to develop the Free Radical Generator (FRG) technology. Now, the Company is leveraging the expertise of Somnio Group for further development.

    Most recently, the Australians announced that commercialization activities would resume in Australia with two new products. These are the Air Conditioning Environmental Remediation Treatment (ACERT) and the Whole of Room Air Purifier (WRAP). In addition, PuriflOH built relationships with Aspen Medical, a healthcare solutions company, and Osmoflo, a water treatment company. Both partners play an important role in the future commercialization of the products.

    The Company is still in the red, but this is characteristic of the relatively early stage. However, the loss was significantly reduced in the fiscal year. In addition, the Company secured an AUD 1 million financing facility from its major shareholder Dilato. Currently, PuriflOH is valued at AUD 53 million. As the products are commercialized, operating income will quickly materialize. Technology-savvy investors should put the shares on their watchlist.

    BAYER AG - Turnaround in sight?

    Climate change is again causing problems for agriculture this year. According to the recently published harvest report by the German Federal Ministry of Agriculture and statements by the farmers' association, heavy rain and hail will lead to a 2.7% decline in the grain harvest this year. Compared to the years 2015 to 2020, this is even a decrease of 4.8%. While too much water has caused problems in this country, water scarcity is a major problem globally. 70% of the world's water is consumed by agriculture. By the end of the decade, demand will already exceed supply. Water is thus becoming a crucial bottleneck factor.

    Even if Bayer is more present in the media through its pharmaceuticals business and its cooperation with the Corona vaccine manufacturer CureVac, whose vaccine has not yet reached the marketing stage due to a lack of vaccine protection, Bayer's strong second pillar is agricultural chemistry. Here, the DAX-listed Company is focusing on targeted research activities to enable water-efficient agriculture. It also develops and markets products and technologies for improved wastewater treatment. Disappointing half-year figures and the lawsuits pending for some time in the USA in connection with carcinogenic fertilizers from the acquired competitor Monsanto led to a significant underperformance of around 10% against the DAX this year. 2021 will undoubtedly be a challenging year for the Group, but analysts expect things to pick up again significantly in 2022. The 2022 P/E ratio is 10, and the stock is currently interesting for anti-cyclical investors.

    KONINKLIJKE PHILIPS NV - Established player with industry-standard valuation

    Koninklijke Philips NV is a leading healthcare technology company with a wide range of products from healthy living and prevention to diagnosis, treatment and home care. The Group uses advanced technologies and sound clinical and consumer insights to provide integrated solutions. The Dutch-based Company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, and consumer health and home care. In Corona times, the air purifier sector has taken on greater importance. The Group is currently valued at around EUR 37 billion, 2 times projected 2022 sales and a 2022 P/E of 24.


    The featured stocks focus on climate, health and water as a resource. In doing so, all companies focus on different areas. Bayer is one of the leading players in agricultural chemicals. After a year of losses, next year should see a return to gratifying profits - this makes the shares interesting. Anyone who wants to invest in a young technology company that offers a range of innovative solutions should take a closer look at the PuriflOH share.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Armin Schulz on January 26th, 2022 | 11:17 CET

    Novavax, CoinSmart, Netflix - A buy after significant setbacks?

    • Investments

    The last few weeks have been tough for vaccine makers, cryptocurrencies and tech companies. In the case of vaccine manufacturers, concerns about a possible endemic disease caused by OmiCron was the reason for falling prices. In addition, there were the rumors about Pfizergate. Cryptocurrencies have been consolidating since early November. Allegedly, the US government is planning a crypto law, but contents are not yet known. For tech companies, the FED's expected interest rate hike, likely to be announced on January 26, brings uncertainty and makes investors rethink their investment strategy. Out of tech stocks, into value stocks. We look at one Company from each sector today.

    Read

    Commented by André Will-Laudien on January 20th, 2022 | 12:51 CET

    Alibaba, Hong Lai Huat, Tencent: Now things are really taking off!

    • Investments

    The Asia region remains on the growth path. The economies of China, Singapore, and Indonesia achieved 4.5 to 6.5% growth in 2021. Prosperity is not yet comparable with the West. But the developed zones around the metropolises have already shown high momentum for years. The real estate market, in particular, is booming in China as well as in Hong Kong, Singapore and Japan. It is uncertain how long the low interest rates will continue to support these markets because the Federal Reserve has already announced that it will exit the liquidity bubble. Who can surprise in the current environment?

    Read

    Commented by Mario Hose on January 20th, 2022 | 11:08 CET

    Cardiol, Novavax, Valneva - Why it's worth buying now!

    • Investments

    The trading week is coming to an end and on Thursday the German benchmark index DAX continues to trade below the psychological mark of 16,000 points at a level of 15,785 points and an increase of 0.10%. The rest of today and Friday remain to make a jump. It will probably depend on the guidance from the U.S., but at the hour, U.S. futures are all green. MDAX last traded at 34,135 points (+0.07%), TecDAX at 3,544 points (+0.07%) and SDAX at 15,626 points up 0.33%. Companies from the biotech sector are again in the focus of the investors today.

    Read